nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—Chest pain—Galantamine—Alzheimer's disease	0.00165	0.00166	CcSEcCtD
Anagrelide—Myalgia—Galantamine—Alzheimer's disease	0.00165	0.00166	CcSEcCtD
Anagrelide—Epistaxis—Memantine—Alzheimer's disease	0.00164	0.00166	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.00164	0.00165	CcSEcCtD
Anagrelide—Sinusitis—Memantine—Alzheimer's disease	0.00164	0.00165	CcSEcCtD
Anagrelide—Sweating—Rivastigmine—Alzheimer's disease	0.00164	0.00165	CcSEcCtD
Anagrelide—Discomfort—Galantamine—Alzheimer's disease	0.00163	0.00164	CcSEcCtD
Anagrelide—Haematuria—Rivastigmine—Alzheimer's disease	0.00163	0.00164	CcSEcCtD
Anagrelide—Hepatobiliary disease—Rivastigmine—Alzheimer's disease	0.00161	0.00163	CcSEcCtD
Anagrelide—Dry mouth—Galantamine—Alzheimer's disease	0.00161	0.00163	CcSEcCtD
Anagrelide—Epistaxis—Rivastigmine—Alzheimer's disease	0.00161	0.00162	CcSEcCtD
Anagrelide—Tinnitus—Donepezil—Alzheimer's disease	0.00161	0.00162	CcSEcCtD
Anagrelide—Sinusitis—Rivastigmine—Alzheimer's disease	0.0016	0.00162	CcSEcCtD
Anagrelide—Confusional state—Galantamine—Alzheimer's disease	0.00159	0.00161	CcSEcCtD
Anagrelide—Haemoglobin—Memantine—Alzheimer's disease	0.00157	0.00159	CcSEcCtD
Anagrelide—Rhinitis—Memantine—Alzheimer's disease	0.00157	0.00158	CcSEcCtD
Anagrelide—Haemorrhage—Memantine—Alzheimer's disease	0.00157	0.00158	CcSEcCtD
Anagrelide—Hepatitis—Memantine—Alzheimer's disease	0.00157	0.00158	CcSEcCtD
Anagrelide—Hypoaesthesia—Memantine—Alzheimer's disease	0.00156	0.00157	CcSEcCtD
Anagrelide—Shock—Galantamine—Alzheimer's disease	0.00155	0.00157	CcSEcCtD
Anagrelide—Pharyngitis—Memantine—Alzheimer's disease	0.00155	0.00157	CcSEcCtD
Anagrelide—Nervous system disorder—Galantamine—Alzheimer's disease	0.00155	0.00156	CcSEcCtD
Anagrelide—Thrombocytopenia—Galantamine—Alzheimer's disease	0.00155	0.00156	CcSEcCtD
Anagrelide—Chills—Donepezil—Alzheimer's disease	0.00155	0.00156	CcSEcCtD
Anagrelide—Urinary tract disorder—Memantine—Alzheimer's disease	0.00155	0.00156	CcSEcCtD
Anagrelide—Tachycardia—Galantamine—Alzheimer's disease	0.00154	0.00156	CcSEcCtD
Anagrelide—Oedema peripheral—Memantine—Alzheimer's disease	0.00154	0.00156	CcSEcCtD
Anagrelide—Arrhythmia—Donepezil—Alzheimer's disease	0.00154	0.00155	CcSEcCtD
Anagrelide—Haemoglobin—Rivastigmine—Alzheimer's disease	0.00154	0.00155	CcSEcCtD
Anagrelide—Connective tissue disorder—Memantine—Alzheimer's disease	0.00154	0.00155	CcSEcCtD
Anagrelide—Rhinitis—Rivastigmine—Alzheimer's disease	0.00154	0.00155	CcSEcCtD
Anagrelide—Skin disorder—Galantamine—Alzheimer's disease	0.00154	0.00155	CcSEcCtD
Anagrelide—Urethral disorder—Memantine—Alzheimer's disease	0.00153	0.00155	CcSEcCtD
Anagrelide—Haemorrhage—Rivastigmine—Alzheimer's disease	0.00153	0.00155	CcSEcCtD
Anagrelide—Hepatitis—Rivastigmine—Alzheimer's disease	0.00153	0.00155	CcSEcCtD
Anagrelide—Hyperhidrosis—Galantamine—Alzheimer's disease	0.00153	0.00154	CcSEcCtD
Anagrelide—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.00152	0.00154	CcSEcCtD
Anagrelide—Alopecia—Donepezil—Alzheimer's disease	0.00152	0.00154	CcSEcCtD
Anagrelide—Pharyngitis—Rivastigmine—Alzheimer's disease	0.00152	0.00153	CcSEcCtD
Anagrelide—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.00151	0.00153	CcSEcCtD
Anagrelide—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.00151	0.00152	CcSEcCtD
Anagrelide—Visual impairment—Memantine—Alzheimer's disease	0.00151	0.00152	CcSEcCtD
Anagrelide—Anorexia—Galantamine—Alzheimer's disease	0.00151	0.00152	CcSEcCtD
Anagrelide—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.0015	0.00152	CcSEcCtD
Anagrelide—Urethral disorder—Rivastigmine—Alzheimer's disease	0.0015	0.00152	CcSEcCtD
Anagrelide—Malnutrition—Donepezil—Alzheimer's disease	0.0015	0.00152	CcSEcCtD
Anagrelide—Flatulence—Donepezil—Alzheimer's disease	0.00148	0.00149	CcSEcCtD
Anagrelide—Hypotension—Galantamine—Alzheimer's disease	0.00148	0.00149	CcSEcCtD
Anagrelide—Visual impairment—Rivastigmine—Alzheimer's disease	0.00148	0.00149	CcSEcCtD
Anagrelide—Tension—Donepezil—Alzheimer's disease	0.00147	0.00149	CcSEcCtD
Anagrelide—Eye disorder—Memantine—Alzheimer's disease	0.00146	0.00148	CcSEcCtD
Anagrelide—Tinnitus—Memantine—Alzheimer's disease	0.00146	0.00147	CcSEcCtD
Anagrelide—Nervousness—Donepezil—Alzheimer's disease	0.00146	0.00147	CcSEcCtD
Anagrelide—Cardiac disorder—Memantine—Alzheimer's disease	0.00145	0.00147	CcSEcCtD
Anagrelide—Back pain—Donepezil—Alzheimer's disease	0.00145	0.00147	CcSEcCtD
Anagrelide—Muscle spasms—Donepezil—Alzheimer's disease	0.00144	0.00146	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.00144	0.00145	CcSEcCtD
Anagrelide—Eye disorder—Rivastigmine—Alzheimer's disease	0.00143	0.00144	CcSEcCtD
Anagrelide—Insomnia—Galantamine—Alzheimer's disease	0.00143	0.00144	CcSEcCtD
Anagrelide—Tinnitus—Rivastigmine—Alzheimer's disease	0.00143	0.00144	CcSEcCtD
Anagrelide—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.00142	0.00143	CcSEcCtD
Anagrelide—Paraesthesia—Galantamine—Alzheimer's disease	0.00142	0.00143	CcSEcCtD
Anagrelide—Vision blurred—Donepezil—Alzheimer's disease	0.00141	0.00143	CcSEcCtD
Anagrelide—Mediastinal disorder—Memantine—Alzheimer's disease	0.00141	0.00142	CcSEcCtD
Anagrelide—Somnolence—Galantamine—Alzheimer's disease	0.0014	0.00142	CcSEcCtD
Anagrelide—Chills—Memantine—Alzheimer's disease	0.0014	0.00142	CcSEcCtD
Anagrelide—Arrhythmia—Memantine—Alzheimer's disease	0.0014	0.00141	CcSEcCtD
Anagrelide—Ill-defined disorder—Donepezil—Alzheimer's disease	0.00139	0.00141	CcSEcCtD
Anagrelide—Dyspepsia—Galantamine—Alzheimer's disease	0.00139	0.0014	CcSEcCtD
Anagrelide—Anaemia—Donepezil—Alzheimer's disease	0.00139	0.0014	CcSEcCtD
Anagrelide—Alopecia—Memantine—Alzheimer's disease	0.00138	0.0014	CcSEcCtD
Anagrelide—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.00138	0.00139	CcSEcCtD
Anagrelide—Chills—Rivastigmine—Alzheimer's disease	0.00137	0.00139	CcSEcCtD
Anagrelide—Decreased appetite—Galantamine—Alzheimer's disease	0.00137	0.00139	CcSEcCtD
Anagrelide—Arrhythmia—Rivastigmine—Alzheimer's disease	0.00137	0.00138	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.00136	0.00138	CcSEcCtD
Anagrelide—Malnutrition—Memantine—Alzheimer's disease	0.00136	0.00138	CcSEcCtD
Anagrelide—Fatigue—Galantamine—Alzheimer's disease	0.00136	0.00138	CcSEcCtD
Anagrelide—Malaise—Donepezil—Alzheimer's disease	0.00135	0.00137	CcSEcCtD
Anagrelide—Alopecia—Rivastigmine—Alzheimer's disease	0.00135	0.00137	CcSEcCtD
Anagrelide—Constipation—Galantamine—Alzheimer's disease	0.00135	0.00136	CcSEcCtD
Anagrelide—Syncope—Donepezil—Alzheimer's disease	0.00135	0.00136	CcSEcCtD
Anagrelide—Flatulence—Memantine—Alzheimer's disease	0.00134	0.00136	CcSEcCtD
Anagrelide—Tension—Memantine—Alzheimer's disease	0.00134	0.00135	CcSEcCtD
Anagrelide—Malnutrition—Rivastigmine—Alzheimer's disease	0.00133	0.00135	CcSEcCtD
Anagrelide—Nervousness—Memantine—Alzheimer's disease	0.00132	0.00134	CcSEcCtD
Anagrelide—Loss of consciousness—Donepezil—Alzheimer's disease	0.00132	0.00133	CcSEcCtD
Anagrelide—Back pain—Memantine—Alzheimer's disease	0.00132	0.00133	CcSEcCtD
Anagrelide—Flatulence—Rivastigmine—Alzheimer's disease	0.00131	0.00133	CcSEcCtD
Anagrelide—Cough—Donepezil—Alzheimer's disease	0.00131	0.00132	CcSEcCtD
Anagrelide—Tension—Rivastigmine—Alzheimer's disease	0.00131	0.00132	CcSEcCtD
Anagrelide—Feeling abnormal—Galantamine—Alzheimer's disease	0.0013	0.00131	CcSEcCtD
Anagrelide—Convulsion—Donepezil—Alzheimer's disease	0.0013	0.00131	CcSEcCtD
Anagrelide—Hypertension—Donepezil—Alzheimer's disease	0.0013	0.00131	CcSEcCtD
Anagrelide—Nervousness—Rivastigmine—Alzheimer's disease	0.00129	0.00131	CcSEcCtD
Anagrelide—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.00129	0.0013	CcSEcCtD
Anagrelide—Back pain—Rivastigmine—Alzheimer's disease	0.00129	0.0013	CcSEcCtD
Anagrelide—Vision blurred—Memantine—Alzheimer's disease	0.00128	0.0013	CcSEcCtD
Anagrelide—Muscle spasms—Rivastigmine—Alzheimer's disease	0.00128	0.00129	CcSEcCtD
Anagrelide—Chest pain—Donepezil—Alzheimer's disease	0.00128	0.00129	CcSEcCtD
Anagrelide—Arthralgia—Donepezil—Alzheimer's disease	0.00128	0.00129	CcSEcCtD
Anagrelide—Myalgia—Donepezil—Alzheimer's disease	0.00128	0.00129	CcSEcCtD
Anagrelide—Ill-defined disorder—Memantine—Alzheimer's disease	0.00126	0.00128	CcSEcCtD
Anagrelide—Discomfort—Donepezil—Alzheimer's disease	0.00126	0.00127	CcSEcCtD
Anagrelide—Anaemia—Memantine—Alzheimer's disease	0.00126	0.00127	CcSEcCtD
Anagrelide—Vision blurred—Rivastigmine—Alzheimer's disease	0.00126	0.00127	CcSEcCtD
Anagrelide—Dry mouth—Donepezil—Alzheimer's disease	0.00125	0.00126	CcSEcCtD
Anagrelide—Abdominal pain—Galantamine—Alzheimer's disease	0.00125	0.00126	CcSEcCtD
Anagrelide—Body temperature increased—Galantamine—Alzheimer's disease	0.00125	0.00126	CcSEcCtD
Anagrelide—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.00124	0.00125	CcSEcCtD
Anagrelide—Confusional state—Donepezil—Alzheimer's disease	0.00123	0.00125	CcSEcCtD
Anagrelide—Anaemia—Rivastigmine—Alzheimer's disease	0.00123	0.00124	CcSEcCtD
Anagrelide—Malaise—Memantine—Alzheimer's disease	0.00123	0.00124	CcSEcCtD
Anagrelide—Oedema—Donepezil—Alzheimer's disease	0.00122	0.00124	CcSEcCtD
Anagrelide—Syncope—Memantine—Alzheimer's disease	0.00122	0.00123	CcSEcCtD
Anagrelide—Infection—Donepezil—Alzheimer's disease	0.00122	0.00123	CcSEcCtD
Anagrelide—Shock—Donepezil—Alzheimer's disease	0.00121	0.00122	CcSEcCtD
Anagrelide—Palpitations—Memantine—Alzheimer's disease	0.0012	0.00122	CcSEcCtD
Anagrelide—Malaise—Rivastigmine—Alzheimer's disease	0.0012	0.00121	CcSEcCtD
Anagrelide—Nervous system disorder—Donepezil—Alzheimer's disease	0.0012	0.00121	CcSEcCtD
Anagrelide—Thrombocytopenia—Donepezil—Alzheimer's disease	0.0012	0.00121	CcSEcCtD
Anagrelide—Loss of consciousness—Memantine—Alzheimer's disease	0.0012	0.00121	CcSEcCtD
Anagrelide—Syncope—Rivastigmine—Alzheimer's disease	0.0012	0.00121	CcSEcCtD
Anagrelide—Cough—Memantine—Alzheimer's disease	0.00119	0.0012	CcSEcCtD
Anagrelide—Hyperhidrosis—Donepezil—Alzheimer's disease	0.00118	0.0012	CcSEcCtD
Anagrelide—Convulsion—Memantine—Alzheimer's disease	0.00118	0.00119	CcSEcCtD
Anagrelide—Palpitations—Rivastigmine—Alzheimer's disease	0.00118	0.00119	CcSEcCtD
Anagrelide—Hypertension—Memantine—Alzheimer's disease	0.00118	0.00119	CcSEcCtD
Anagrelide—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.00117	0.00118	CcSEcCtD
Anagrelide—Anorexia—Donepezil—Alzheimer's disease	0.00117	0.00118	CcSEcCtD
Anagrelide—Cough—Rivastigmine—Alzheimer's disease	0.00116	0.00117	CcSEcCtD
Anagrelide—Myalgia—Memantine—Alzheimer's disease	0.00116	0.00117	CcSEcCtD
Anagrelide—Chest pain—Memantine—Alzheimer's disease	0.00116	0.00117	CcSEcCtD
Anagrelide—Arthralgia—Memantine—Alzheimer's disease	0.00116	0.00117	CcSEcCtD
Anagrelide—Convulsion—Rivastigmine—Alzheimer's disease	0.00115	0.00117	CcSEcCtD
Anagrelide—Hypertension—Rivastigmine—Alzheimer's disease	0.00115	0.00116	CcSEcCtD
Anagrelide—Discomfort—Memantine—Alzheimer's disease	0.00115	0.00116	CcSEcCtD
Anagrelide—Hypotension—Donepezil—Alzheimer's disease	0.00114	0.00116	CcSEcCtD
Anagrelide—Myalgia—Rivastigmine—Alzheimer's disease	0.00113	0.00115	CcSEcCtD
Anagrelide—Chest pain—Rivastigmine—Alzheimer's disease	0.00113	0.00115	CcSEcCtD
Anagrelide—Arthralgia—Rivastigmine—Alzheimer's disease	0.00113	0.00115	CcSEcCtD
Anagrelide—Dry mouth—Memantine—Alzheimer's disease	0.00113	0.00115	CcSEcCtD
Anagrelide—Asthenia—Galantamine—Alzheimer's disease	0.00113	0.00114	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.00113	0.00114	CcSEcCtD
Anagrelide—Confusional state—Memantine—Alzheimer's disease	0.00112	0.00113	CcSEcCtD
Anagrelide—Discomfort—Rivastigmine—Alzheimer's disease	0.00112	0.00113	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.00112	0.00113	CcSEcCtD
Anagrelide—Oedema—Memantine—Alzheimer's disease	0.00111	0.00112	CcSEcCtD
Anagrelide—Dry mouth—Rivastigmine—Alzheimer's disease	0.00111	0.00112	CcSEcCtD
Anagrelide—Insomnia—Donepezil—Alzheimer's disease	0.00111	0.00112	CcSEcCtD
Anagrelide—Infection—Memantine—Alzheimer's disease	0.0011	0.00112	CcSEcCtD
Anagrelide—Paraesthesia—Donepezil—Alzheimer's disease	0.0011	0.00111	CcSEcCtD
Anagrelide—Confusional state—Rivastigmine—Alzheimer's disease	0.0011	0.00111	CcSEcCtD
Anagrelide—Shock—Memantine—Alzheimer's disease	0.00109	0.0011	CcSEcCtD
Anagrelide—Dyspnoea—Donepezil—Alzheimer's disease	0.00109	0.0011	CcSEcCtD
Anagrelide—Nervous system disorder—Memantine—Alzheimer's disease	0.00109	0.0011	CcSEcCtD
Anagrelide—Somnolence—Donepezil—Alzheimer's disease	0.00109	0.0011	CcSEcCtD
Anagrelide—Thrombocytopenia—Memantine—Alzheimer's disease	0.00109	0.0011	CcSEcCtD
Anagrelide—Oedema—Rivastigmine—Alzheimer's disease	0.00109	0.0011	CcSEcCtD
Anagrelide—Tachycardia—Memantine—Alzheimer's disease	0.00109	0.0011	CcSEcCtD
Anagrelide—Diarrhoea—Galantamine—Alzheimer's disease	0.00108	0.00109	CcSEcCtD
Anagrelide—Infection—Rivastigmine—Alzheimer's disease	0.00108	0.00109	CcSEcCtD
Anagrelide—Skin disorder—Memantine—Alzheimer's disease	0.00108	0.00109	CcSEcCtD
Anagrelide—Dyspepsia—Donepezil—Alzheimer's disease	0.00108	0.00109	CcSEcCtD
Anagrelide—Hyperhidrosis—Memantine—Alzheimer's disease	0.00108	0.00109	CcSEcCtD
Anagrelide—Shock—Rivastigmine—Alzheimer's disease	0.00107	0.00108	CcSEcCtD
Anagrelide—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.00107	0.00108	CcSEcCtD
Anagrelide—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.00107	0.00108	CcSEcCtD
Anagrelide—Decreased appetite—Donepezil—Alzheimer's disease	0.00106	0.00107	CcSEcCtD
Anagrelide—Tachycardia—Rivastigmine—Alzheimer's disease	0.00106	0.00107	CcSEcCtD
Anagrelide—Anorexia—Memantine—Alzheimer's disease	0.00106	0.00107	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.00106	0.00107	CcSEcCtD
Anagrelide—Skin disorder—Rivastigmine—Alzheimer's disease	0.00106	0.00107	CcSEcCtD
Anagrelide—Fatigue—Donepezil—Alzheimer's disease	0.00106	0.00107	CcSEcCtD
Anagrelide—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.00105	0.00106	CcSEcCtD
Anagrelide—Pain—Donepezil—Alzheimer's disease	0.00105	0.00106	CcSEcCtD
Anagrelide—Constipation—Donepezil—Alzheimer's disease	0.00105	0.00106	CcSEcCtD
Anagrelide—Dizziness—Galantamine—Alzheimer's disease	0.00105	0.00106	CcSEcCtD
Anagrelide—Hypotension—Memantine—Alzheimer's disease	0.00104	0.00105	CcSEcCtD
Anagrelide—Anorexia—Rivastigmine—Alzheimer's disease	0.00104	0.00105	CcSEcCtD
Anagrelide—Hypotension—Rivastigmine—Alzheimer's disease	0.00102	0.00103	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.00101	0.00102	CcSEcCtD
Anagrelide—Feeling abnormal—Donepezil—Alzheimer's disease	0.00101	0.00102	CcSEcCtD
Anagrelide—Insomnia—Memantine—Alzheimer's disease	0.00101	0.00102	CcSEcCtD
Anagrelide—Vomiting—Galantamine—Alzheimer's disease	0.001	0.00101	CcSEcCtD
Anagrelide—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.001	0.00101	CcSEcCtD
Anagrelide—Paraesthesia—Memantine—Alzheimer's disease	0.000999	0.00101	CcSEcCtD
Anagrelide—Rash—Galantamine—Alzheimer's disease	0.000996	0.00101	CcSEcCtD
Anagrelide—Dermatitis—Galantamine—Alzheimer's disease	0.000996	0.00101	CcSEcCtD
Anagrelide—Dyspnoea—Memantine—Alzheimer's disease	0.000991	0.001	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000991	0.001	CcSEcCtD
Anagrelide—Headache—Galantamine—Alzheimer's disease	0.00099	0.001	CcSEcCtD
Anagrelide—Somnolence—Memantine—Alzheimer's disease	0.000989	0.000998	CcSEcCtD
Anagrelide—Insomnia—Rivastigmine—Alzheimer's disease	0.000984	0.000993	CcSEcCtD
Anagrelide—Dyspepsia—Memantine—Alzheimer's disease	0.000979	0.000988	CcSEcCtD
Anagrelide—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000977	0.000986	CcSEcCtD
Anagrelide—Urticaria—Donepezil—Alzheimer's disease	0.000973	0.000982	CcSEcCtD
Anagrelide—Dyspnoea—Rivastigmine—Alzheimer's disease	0.00097	0.000979	CcSEcCtD
Anagrelide—Abdominal pain—Donepezil—Alzheimer's disease	0.000968	0.000978	CcSEcCtD
Anagrelide—Body temperature increased—Donepezil—Alzheimer's disease	0.000968	0.000978	CcSEcCtD
Anagrelide—Somnolence—Rivastigmine—Alzheimer's disease	0.000967	0.000976	CcSEcCtD
Anagrelide—Decreased appetite—Memantine—Alzheimer's disease	0.000967	0.000976	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.00096	0.000969	CcSEcCtD
Anagrelide—Fatigue—Memantine—Alzheimer's disease	0.000959	0.000968	CcSEcCtD
Anagrelide—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000958	0.000967	CcSEcCtD
Anagrelide—Pain—Memantine—Alzheimer's disease	0.000951	0.00096	CcSEcCtD
Anagrelide—Constipation—Memantine—Alzheimer's disease	0.000951	0.00096	CcSEcCtD
Anagrelide—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000946	0.000955	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000939	0.000948	CcSEcCtD
Anagrelide—Nausea—Galantamine—Alzheimer's disease	0.000939	0.000948	CcSEcCtD
Anagrelide—Fatigue—Rivastigmine—Alzheimer's disease	0.000938	0.000947	CcSEcCtD
Anagrelide—Constipation—Rivastigmine—Alzheimer's disease	0.00093	0.000939	CcSEcCtD
Anagrelide—Pain—Rivastigmine—Alzheimer's disease	0.00093	0.000939	CcSEcCtD
Anagrelide—Feeling abnormal—Memantine—Alzheimer's disease	0.000916	0.000925	CcSEcCtD
Anagrelide—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000909	0.000918	CcSEcCtD
Anagrelide—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000897	0.000905	CcSEcCtD
Anagrelide—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.00089	0.000898	CcSEcCtD
Anagrelide—Urticaria—Memantine—Alzheimer's disease	0.000883	0.000892	CcSEcCtD
Anagrelide—Abdominal pain—Memantine—Alzheimer's disease	0.000879	0.000888	CcSEcCtD
Anagrelide—Body temperature increased—Memantine—Alzheimer's disease	0.000879	0.000888	CcSEcCtD
Anagrelide—Asthenia—Donepezil—Alzheimer's disease	0.000879	0.000887	CcSEcCtD
Anagrelide—Pruritus—Donepezil—Alzheimer's disease	0.000867	0.000875	CcSEcCtD
Anagrelide—Urticaria—Rivastigmine—Alzheimer's disease	0.000864	0.000873	CcSEcCtD
Anagrelide—Abdominal pain—Rivastigmine—Alzheimer's disease	0.00086	0.000868	CcSEcCtD
Anagrelide—Body temperature increased—Rivastigmine—Alzheimer's disease	0.00086	0.000868	CcSEcCtD
Anagrelide—Diarrhoea—Donepezil—Alzheimer's disease	0.000838	0.000846	CcSEcCtD
Anagrelide—Dizziness—Donepezil—Alzheimer's disease	0.00081	0.000818	CcSEcCtD
Anagrelide—Asthenia—Memantine—Alzheimer's disease	0.000798	0.000806	CcSEcCtD
Anagrelide—Pruritus—Memantine—Alzheimer's disease	0.000787	0.000794	CcSEcCtD
Anagrelide—Asthenia—Rivastigmine—Alzheimer's disease	0.000781	0.000788	CcSEcCtD
Anagrelide—Vomiting—Donepezil—Alzheimer's disease	0.000779	0.000786	CcSEcCtD
Anagrelide—Rash—Donepezil—Alzheimer's disease	0.000772	0.00078	CcSEcCtD
Anagrelide—Dermatitis—Donepezil—Alzheimer's disease	0.000772	0.000779	CcSEcCtD
Anagrelide—Pruritus—Rivastigmine—Alzheimer's disease	0.00077	0.000777	CcSEcCtD
Anagrelide—Headache—Donepezil—Alzheimer's disease	0.000767	0.000775	CcSEcCtD
Anagrelide—Diarrhoea—Memantine—Alzheimer's disease	0.000761	0.000768	CcSEcCtD
Anagrelide—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000744	0.000752	CcSEcCtD
Anagrelide—Dizziness—Memantine—Alzheimer's disease	0.000735	0.000742	CcSEcCtD
Anagrelide—Nausea—Donepezil—Alzheimer's disease	0.000728	0.000734	CcSEcCtD
Anagrelide—Dizziness—Rivastigmine—Alzheimer's disease	0.000719	0.000726	CcSEcCtD
Anagrelide—Vomiting—Memantine—Alzheimer's disease	0.000707	0.000714	CcSEcCtD
Anagrelide—Rash—Memantine—Alzheimer's disease	0.000701	0.000708	CcSEcCtD
Anagrelide—Dermatitis—Memantine—Alzheimer's disease	0.000701	0.000707	CcSEcCtD
Anagrelide—Headache—Memantine—Alzheimer's disease	0.000697	0.000703	CcSEcCtD
Anagrelide—Vomiting—Rivastigmine—Alzheimer's disease	0.000692	0.000698	CcSEcCtD
Anagrelide—Rash—Rivastigmine—Alzheimer's disease	0.000686	0.000693	CcSEcCtD
Anagrelide—Dermatitis—Rivastigmine—Alzheimer's disease	0.000685	0.000692	CcSEcCtD
Anagrelide—Headache—Rivastigmine—Alzheimer's disease	0.000682	0.000688	CcSEcCtD
Anagrelide—Nausea—Memantine—Alzheimer's disease	0.000661	0.000667	CcSEcCtD
Anagrelide—Nausea—Rivastigmine—Alzheimer's disease	0.000646	0.000652	CcSEcCtD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—NOS2—Alzheimer's disease	0.00038	0.04	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—HTR6—Alzheimer's disease	0.000328	0.0346	CbGpPWpGaD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—NOS3—Alzheimer's disease	0.000305	0.0321	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—DHCR24—Alzheimer's disease	0.000296	0.0312	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—MAP2—Alzheimer's disease	0.000246	0.0259	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—IAPP—Alzheimer's disease	0.000213	0.0224	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—CRH—Alzheimer's disease	0.000207	0.0218	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—HSD17B10—Alzheimer's disease	0.000205	0.0216	CbGpPWpGaD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—CYP2D6—Alzheimer's disease	0.000204	0.0215	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—NPS—Alzheimer's disease	0.000196	0.0206	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—DOCK3—Alzheimer's disease	0.000179	0.0189	CbGpPWpGaD
Anagrelide—CYP1A2—Xenobiotics—CYP2D6—Alzheimer's disease	0.000171	0.018	CbGpPWpGaD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP2D6—Alzheimer's disease	0.000164	0.0173	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP46A1—Alzheimer's disease	0.00016	0.0168	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP46A1—Alzheimer's disease	0.000158	0.0166	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—NOS2—Alzheimer's disease	0.000148	0.0156	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—ACHE—Alzheimer's disease	0.000138	0.0145	CbGpPWpGaD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—ESR1—Alzheimer's disease	0.000131	0.0138	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP46A1—Alzheimer's disease	0.00013	0.0136	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—CYP2D6—Alzheimer's disease	0.000127	0.0133	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—NOS3—Alzheimer's disease	0.000119	0.0125	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—MAOB—Alzheimer's disease	0.000118	0.0124	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CDK5—Alzheimer's disease	0.000111	0.0117	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—Alzheimer's disease	9.68e-05	0.0102	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CLU—Alzheimer's disease	8.76e-05	0.00921	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS1—Alzheimer's disease	8.36e-05	0.0088	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PYY—Alzheimer's disease	8.07e-05	0.0085	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—A2M—Alzheimer's disease	7.8e-05	0.00821	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—MAOB—Alzheimer's disease	7.73e-05	0.00813	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PYY—Alzheimer's disease	7.33e-05	0.00771	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—CALM1—Alzheimer's disease	7.25e-05	0.00763	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—APOE—Alzheimer's disease	7.23e-05	0.00761	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2D6—Alzheimer's disease	7.09e-05	0.00746	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP2D6—Alzheimer's disease	6.99e-05	0.00736	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP46A1—Alzheimer's disease	6.88e-05	0.00724	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP46A1—Alzheimer's disease	6.79e-05	0.00714	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—HTR6—Alzheimer's disease	6.74e-05	0.00709	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—INPP5D—Alzheimer's disease	6.71e-05	0.00706	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TF—Alzheimer's disease	6.64e-05	0.00698	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CDK5—Alzheimer's disease	6.36e-05	0.00669	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—GSK3B—Alzheimer's disease	6.26e-05	0.00659	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HTR6—Alzheimer's disease	6.12e-05	0.00644	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—GAB2—Alzheimer's disease	6.07e-05	0.00639	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—LPL—Alzheimer's disease	5.96e-05	0.00627	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—Alzheimer's disease	5.92e-05	0.00623	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—APP—Alzheimer's disease	5.91e-05	0.00622	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—Alzheimer's disease	5.86e-05	0.00616	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2D6—Alzheimer's disease	5.74e-05	0.00604	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GAL—Alzheimer's disease	5.6e-05	0.00589	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—Alzheimer's disease	5.54e-05	0.00583	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GAL—Alzheimer's disease	5.08e-05	0.00535	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TTR—Alzheimer's disease	4.96e-05	0.00521	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SOD1—Alzheimer's disease	4.82e-05	0.00507	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—Alzheimer's disease	4.77e-05	0.00502	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF2—Alzheimer's disease	4.58e-05	0.00482	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—NPY—Alzheimer's disease	4.4e-05	0.00463	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IAPP—Alzheimer's disease	4.37e-05	0.0046	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PYY—Alzheimer's disease	4.33e-05	0.00456	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CRH—Alzheimer's disease	4.24e-05	0.00446	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PRKCG—Alzheimer's disease	4.13e-05	0.00434	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—MAOB—Alzheimer's disease	4.11e-05	0.00432	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—NPS—Alzheimer's disease	4.02e-05	0.00423	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NPY—Alzheimer's disease	3.99e-05	0.0042	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IAPP—Alzheimer's disease	3.97e-05	0.00417	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—DHCR24—Alzheimer's disease	3.96e-05	0.00417	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CRH—Alzheimer's disease	3.85e-05	0.00405	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GAB2—Alzheimer's disease	3.84e-05	0.00404	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—SST—Alzheimer's disease	3.84e-05	0.00404	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDK5—Alzheimer's disease	3.76e-05	0.00395	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—APP—Alzheimer's disease	3.74e-05	0.00393	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NPS—Alzheimer's disease	3.65e-05	0.00384	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PPP3CA—Alzheimer's disease	3.63e-05	0.00382	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR6—Alzheimer's disease	3.61e-05	0.0038	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAU—Alzheimer's disease	3.61e-05	0.0038	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CALM1—Alzheimer's disease	3.57e-05	0.00376	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PLCB1—Alzheimer's disease	3.53e-05	0.00371	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CAV1—Alzheimer's disease	3.53e-05	0.00371	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GAB2—Alzheimer's disease	3.48e-05	0.00367	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—SST—Alzheimer's disease	3.48e-05	0.00367	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Alzheimer's disease	3.42e-05	0.0036	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—APP—Alzheimer's disease	3.39e-05	0.00357	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—F2—Alzheimer's disease	3.36e-05	0.00353	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS2—Alzheimer's disease	3.32e-05	0.00349	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSENEN—Alzheimer's disease	3.28e-05	0.00345	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APH1A—Alzheimer's disease	3.24e-05	0.00341	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—Alzheimer's disease	3.2e-05	0.00337	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PLCB1—Alzheimer's disease	3.2e-05	0.00337	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Alzheimer's disease	3.19e-05	0.00335	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NCSTN—Alzheimer's disease	3.15e-05	0.00332	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—PTGS1—Alzheimer's disease	3.11e-05	0.00327	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LRP1—Alzheimer's disease	3.07e-05	0.00323	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP2D6—Alzheimer's disease	3.05e-05	0.00321	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP2D6—Alzheimer's disease	3.01e-05	0.00317	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GFAP—Alzheimer's disease	3e-05	0.00316	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GAL—Alzheimer's disease	3e-05	0.00316	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF1—Alzheimer's disease	2.94e-05	0.00309	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLD3—Alzheimer's disease	2.86e-05	0.00301	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—Alzheimer's disease	2.7e-05	0.00284	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS3—Alzheimer's disease	2.67e-05	0.0028	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—A2M—Alzheimer's disease	2.65e-05	0.00278	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP46A1—Alzheimer's disease	2.64e-05	0.00278	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PRKCG—Alzheimer's disease	2.61e-05	0.00274	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSEN2—Alzheimer's disease	2.56e-05	0.0027	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—Alzheimer's disease	2.48e-05	0.00261	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCR5—Alzheimer's disease	2.47e-05	0.0026	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—HTR2A—Alzheimer's disease	2.42e-05	0.00255	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PRKCG—Alzheimer's disease	2.37e-05	0.00249	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NPY—Alzheimer's disease	2.36e-05	0.00248	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IAPP—Alzheimer's disease	2.34e-05	0.00247	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Alzheimer's disease	2.31e-05	0.00243	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Alzheimer's disease	2.31e-05	0.00243	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CRH—Alzheimer's disease	2.28e-05	0.00239	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR5—Alzheimer's disease	2.24e-05	0.00236	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HTR2A—Alzheimer's disease	2.2e-05	0.00231	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NPS—Alzheimer's disease	2.16e-05	0.00227	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PPP3CA—Alzheimer's disease	2.15e-05	0.00226	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—F2—Alzheimer's disease	2.12e-05	0.00223	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTK2B—Alzheimer's disease	2.12e-05	0.00223	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GAB2—Alzheimer's disease	2.06e-05	0.00217	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NTRK2—Alzheimer's disease	2.06e-05	0.00217	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SST—Alzheimer's disease	2.06e-05	0.00217	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CALM1—Alzheimer's disease	2.05e-05	0.00216	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GSK3A—Alzheimer's disease	2.04e-05	0.00215	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APP—Alzheimer's disease	2.01e-05	0.00211	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—F2—Alzheimer's disease	1.93e-05	0.00203	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—Alzheimer's disease	1.92e-05	0.00202	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLCB1—Alzheimer's disease	1.89e-05	0.00199	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGFR—Alzheimer's disease	1.77e-05	0.00186	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DHCR24—Alzheimer's disease	1.76e-05	0.00186	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—Alzheimer's disease	1.76e-05	0.00185	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CREB1—Alzheimer's disease	1.75e-05	0.00185	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADAM10—Alzheimer's disease	1.72e-05	0.00181	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—Alzheimer's disease	1.72e-05	0.00181	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—Alzheimer's disease	1.64e-05	0.00173	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—S100B—Alzheimer's disease	1.63e-05	0.00172	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF2—Alzheimer's disease	1.55e-05	0.00163	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1R—Alzheimer's disease	1.5e-05	0.00158	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA4—Alzheimer's disease	1.5e-05	0.00158	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—A2M—Alzheimer's disease	1.47e-05	0.00154	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—Alzheimer's disease	1.45e-05	0.00153	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LPL—Alzheimer's disease	1.44e-05	0.00151	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MEF2C—Alzheimer's disease	1.43e-05	0.0015	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GAPDHS—Alzheimer's disease	1.41e-05	0.00148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCG—Alzheimer's disease	1.4e-05	0.00147	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGF—Alzheimer's disease	1.36e-05	0.00143	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ATP5A1—Alzheimer's disease	1.34e-05	0.00141	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR5—Alzheimer's disease	1.33e-05	0.0014	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR2A—Alzheimer's disease	1.3e-05	0.00137	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLD3—Alzheimer's disease	1.27e-05	0.00134	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—Alzheimer's disease	1.27e-05	0.00134	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—INPP5D—Alzheimer's disease	1.26e-05	0.00133	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—Alzheimer's disease	1.23e-05	0.00129	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD17B10—Alzheimer's disease	1.22e-05	0.00129	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CALM1—Alzheimer's disease	1.21e-05	0.00127	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOE—Alzheimer's disease	1.21e-05	0.00127	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—Alzheimer's disease	1.21e-05	0.00127	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CAV1—Alzheimer's disease	1.2e-05	0.00126	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—Alzheimer's disease	1.19e-05	0.00126	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP46A1—Alzheimer's disease	1.18e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ESR1—Alzheimer's disease	1.15e-05	0.00121	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—F2—Alzheimer's disease	1.14e-05	0.0012	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ND1—Alzheimer's disease	1.14e-05	0.0012	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH1—Alzheimer's disease	1.11e-05	0.00117	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—Alzheimer's disease	1.11e-05	0.00117	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GSK3B—Alzheimer's disease	1.04e-05	0.0011	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CREB1—Alzheimer's disease	1.04e-05	0.00109	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INS—Alzheimer's disease	1.03e-05	0.00108	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—Alzheimer's disease	1.02e-05	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL2—Alzheimer's disease	1.01e-05	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—Alzheimer's disease	9.97e-06	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—Alzheimer's disease	9.04e-06	0.000951	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—Alzheimer's disease	8.76e-06	0.000921	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—Alzheimer's disease	7.97e-06	0.000839	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—Alzheimer's disease	7.74e-06	0.000815	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—Alzheimer's disease	7.67e-06	0.000807	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—Alzheimer's disease	7.62e-06	0.000802	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TPI1—Alzheimer's disease	7.32e-06	0.000771	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CHAT—Alzheimer's disease	7.32e-06	0.000771	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK8—Alzheimer's disease	7.05e-06	0.000742	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—Alzheimer's disease	7.03e-06	0.00074	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MAOB—Alzheimer's disease	7.02e-06	0.000739	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GAPDH—Alzheimer's disease	6.76e-06	0.000711	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	6.68e-06	0.000703	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	6.62e-06	0.000697	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—A2M—Alzheimer's disease	6.53e-06	0.000687	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—Alzheimer's disease	6.51e-06	0.000685	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—Alzheimer's disease	5.98e-06	0.000629	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	5.82e-06	0.000612	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACHE—Alzheimer's disease	5.68e-06	0.000597	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—INPP5D—Alzheimer's disease	5.61e-06	0.000591	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS1—Alzheimer's disease	5.32e-06	0.00056	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ENO1—Alzheimer's disease	5.32e-06	0.00056	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2D6—Alzheimer's disease	5.22e-06	0.000549	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—BCHE—Alzheimer's disease	4.95e-06	0.00052	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—Alzheimer's disease	4.92e-06	0.000518	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCB1—Alzheimer's disease	4.67e-06	0.000491	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	4.58e-06	0.000482	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCA1—Alzheimer's disease	4.52e-06	0.000476	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—Alzheimer's disease	4.5e-06	0.000474	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—Alzheimer's disease	4.15e-06	0.000437	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARGC1A—Alzheimer's disease	3.9e-06	0.00041	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—Alzheimer's disease	3.88e-06	0.000408	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPL—Alzheimer's disease	3.55e-06	0.000374	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—Alzheimer's disease	3.2e-06	0.000336	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CALM1—Alzheimer's disease	2.99e-06	0.000314	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOE—Alzheimer's disease	2.98e-06	0.000313	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAV1—Alzheimer's disease	2.95e-06	0.00031	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—Alzheimer's disease	2.59e-06	0.000273	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—INS—Alzheimer's disease	2.54e-06	0.000267	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—Alzheimer's disease	2.23e-06	0.000235	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—Alzheimer's disease	2.04e-06	0.000215	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—Alzheimer's disease	1.02e-06	0.000108	CbGpPWpGaD
